Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting
Chronic Lymphocytic Leukaemia
DRUG: Idelalisib|DRUG: Rituximab
Overall Response Rate, Overall Response Rate (ORR) is defined as the proportion of participants who achieve a clinical response as documented within their patient records after the initiation of treatment with idelalisib and rituximab during the observation period., Up to 3 months
Overall Survival, Overall survival (OS) is defined as the interval from the initiation of idelalisib and rituximab to death from any cause, Up to 3 months|Progression-Free Survival, Progression-free survival (PFS) is defined as the interval from the initiation of idelalisib and rituximab to the first documentation of definitive disease progression or death from any cause; definitive disease progression is CLL progression based on documentation in participant records, Up to 3 months|Time to Next Treatment, Time to next treatment (TTNT) is defined as the interval from the initiation of treatment with idelalisib and rituximab to the initiation of next treatment, Up to 3 months|Duration of Response, Duration of response (DOR) is defined as the interval from the first documentation of clinical response to the earlier of the first documentation of definitive disease progression or death from any cause, Up to 3 months|Overall Safety and Tolerability of Idelalisib and Rituximab as Measured by the Incidence of Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs), Up to 3 months|Starting Dose of Idelalisib, Up to 3 months|Proportion of Participants with Dose-Modifications, Treatment Interruptions and Discontinuations of Idelalisib, Up to 3 months|Proportion of Participants For Whom antibiotic Prophylactic Measures were Effective, Up to 3 months
The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting